Intelligent Bio Solutions Inc. filings document a medical technology issuer commercializing rapid, non-invasive fingerprint sweat drug screening and reporting through periodic material-event disclosures. Recent 8-Ks cover operating results, preliminary revenue information, Regulation FD presentations, clinical study program updates tied to the Intelligent Fingerprinting Drug Screening System, and manufacturing disclosures for readers and lateral-flow test strips.
The filing record also includes capital-structure and governance subjects, including common stock issued through warrant exercises and an at-the-market offering agreement, restricted stock awards under the 2019 Long Term Incentive Plan and Australian Sub-Plan, and Nasdaq Capital Market bid-price compliance notices. These disclosures frame the company's product commercialization, regulatory pathway, equity compensation, share count and listing-status matters.
Intelligent Bio Solutions Inc. (INBS) reported first-quarter fiscal 2027 revenue of $1,391,835 for the three months ended September 30, 2026, up 25% year over year and 21% sequentially. It described the quarter as its highest quarterly revenue and third consecutive quarter above $1 million. Cartridge sales were $845,583, up 32% year over year and equal to 61% of revenue; other sales were $281,253, up 52% and 20% of revenue.
Gross profit was $758,004, up 46%, and gross margin was 54.5% versus 46.6% a year earlier. Net loss was $2,668,435, compared with $2,994,992 in the prior-year quarter. Cash and cash equivalents were $5,929,871 as of September 30, 2026, versus $3,992,312 as of June 30, 2026.
On September 9, 2026, the company submitted an FDA 510(k) premarket notification seeking clearance of its Intelligent Fingerprinting Drug Screening System for detection of opiate codeine. It reported method-comparison results above 98% accuracy, above 94% sensitivity and 100% specificity across three independent U.S. clinical sites. It had 516 active customer accounts and 1,978 readers installed as of September 30, 2026.
Intelligent Bio Solutions Inc. (INBS) reported revenue of $1,391,835 for the three months ended September 30, 2026, compared with $1,111,797 a year earlier. Gross profit was $758,004 versus $518,291, while net loss attributable to INBS was $2,658,302 versus $2,983,006. The company submitted a 510(k) premarket notification seeking FDA clearance of its fingerprint drug-screening system for codeine; its three-site study reported accuracy above 98%, sensitivity above 94%, and specificity of 100%.
Cash was $5,929,871 at quarter-end, and operating activities used $2,752,991. Management says cash will be insufficient to fund its current operating plan through at least the next 12 months and additional funds will be required, raising substantial doubt about going concern. A private placement closed September 2, 2026, with approximately $5.0 million in gross proceeds before fees and offering expenses; ATM sales generated $265,373 net of commissions in the quarter. At September 30, 2026, 12,045,102 warrants were outstanding to purchase common shares, versus 3,316,803 shares outstanding; the company says warrant exercise would cause substantial dilution.
Intelligent Bio Solutions Inc. (INBS) is asking stockholders to approve, for Nasdaq Listing Rule 5635(d) purposes, issuance of up to 2,036,659 common shares upon exercise of Series N-2 Warrants issued in a private placement on September 2, 2026. Its virtual annual meeting is scheduled for December 3, 2026; stockholders of record on October 13, 2026, may vote, and 3,316,803 common shares were issued and outstanding and entitled to vote on that record date.
The agenda also includes election of four directors, ratification of UHY LLP as independent auditor for fiscal 2027, an amendment and restatement of the 2019 Plan effective December 3, 2026, advisory executive-pay and pay-frequency votes, and two conditional adjournment authorizations to seek votes for the plan and Nasdaq proposals. The Board recommends a one-year interval for future executive-pay votes and recommends FOR the other listed proposals. Each share carries one vote, and one-third of the issued and outstanding shares entitled to vote constitutes a quorum. Fiscal 2026 total compensation was $661,332 for President and CEO Harry Simeonidis and $521,500 for CFO Spiro Sakiris.
Intelligent Bio Solutions Inc. (INBS) is soliciting votes for its virtual annual meeting on December 3, 2026. The agenda includes electing four directors; ratifying UHY LLP as independent registered public accounting firm for fiscal 2027; approving the 2019 Long Term Incentive Plan as amended and restated effective December 3, 2026; and approving, for Nasdaq Listing Rule 5635(d) purposes, issuance of up to 2,036,659 common shares upon exercise of Series N-2 Warrants issued in a private placement on September 2, 2026. Other proposals address executive compensation, the frequency of future advisory pay votes, and adjournment authority to solicit votes on the plan and warrant proposals.
Common stockholders of record on October 13, 2026 may vote; 3,316,803 shares were issued and outstanding as of that date, with one vote per share. The meeting begins at 4:00 p.m. Eastern Time, and virtual registration closes at 11:59 p.m. Eastern Time on December 2, 2026. The board recommends “FOR” Proposals 1–5, “ONE YEAR” for the frequency vote, and “FOR” both adjournment proposals. Fiscal 2026 total compensation was $661,332 for President and Chief Executive Officer Harry Simeonidis and $521,500 for Chief Financial Officer Spiro Sakiris.
Intelligent Bio Solutions Inc. amended its fiscal 2026 annual report to revise executive-compensation and related-party disclosures and correct duplicate or superseded exhibit-index entries. It adds transaction details for Alyeska Master Fund, L.P., a beneficial owner of more than 5%: approximately $831,368 in gross proceeds from the 2025 warrant inducement transaction and approximately $5.0 million from the December private placement. During fiscal 2026, Alyeska exercised warrants for 216,247 common shares for an aggregate exercise price of $118,109.
For awards approved March 18, 2026, Harry Simeonidis, chief executive officer and president, and Spiro Sakiris, chief financial officer, were each awarded 9,150 time-vesting restricted shares and 21,350 performance-vesting restricted shares. The performance awards vest in tranches tied to a clinical-trial milestone, an FDA submission, and a commercial supply and sales milestone, subject to continued service and the stated vesting conditions.
Intelligent Bio Solutions Inc. adopted amended and restated bylaws effective October 12, 2026. For stockholder-meeting matters other than director elections, the bylaws clarify that approval requires the affirmative vote of holders of a majority in voting power of votes cast. Broker non-votes and abstentions are excluded, and abstentions have no impact on the result. The company also made an investor presentation about its business and operations available on October 13, 2026.
Intelligent Bio Solutions Inc. (INBS) registered 6,211,809 common shares for resale by selling stockholders, all issuable upon exercise of warrants from its September 2026 private placement. The shares comprise 2,036,659 under each of the Series M Pre-Funded, Series N-1 and Series N-2 Warrants, plus 101,832 under Placement Agent Warrants. The Series M, Series N-1 and Placement Agent Warrants are immediately exercisable; Series N-2 Warrants are exercisable after stockholder approval, which INBS agreed to seek at a meeting on or before December 31, 2026.
INBS receives no proceeds from resales, but may receive proceeds from cash warrant exercises and intends to use them for working capital and general corporate purposes. If all specified warrants are exercised for cash, the company estimates gross proceeds of approximately $9.82 million. INBS reported approximately $5.0 million in gross proceeds from the private placement, before fees and expenses and excluding warrant-exercise proceeds. The auditor's report on the incorporated financial statements includes an explanatory paragraph regarding the company's ability to continue as a going concern.
Intelligent Bio Solutions Inc. (INBS) is registering 6,211,809 shares of common stock on Form S-3 for resale by existing holders, all issuable upon exercise of outstanding warrants from a September 2026 private placement and related placement agent warrants. The company itself is not selling any shares in this offering and will not receive proceeds from resales; cash will go to the selling stockholders. INBS may receive up to approximately $9.82 million only if all registered warrants are exercised for cash, and it plans to use any such funds for working capital and general corporate purposes. As of September 14, 2026, 3,316,803 shares of common stock were outstanding, so the registered resale amount is large relative to the current share count, which the company notes could weigh on the trading price if sold rapidly. The prospectus highlights prior Nasdaq bid-price deficiency resolved via a December 2025 reverse stock split and notes that continued listing still depends on meeting ongoing Nasdaq requirements. The company’s auditor has included a going-concern explanatory paragraph in the latest annual financial statements, and the prospectus emphasizes extensive risk factors and forward‑looking statement cautions for prospective investors.